Tris Pharma Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TRIS PHARMA INC, and when can generic versions of TRIS PHARMA INC drugs launch?
TRIS PHARMA INC has twenty-eight approved drugs.
There are eleven US patents protecting TRIS PHARMA INC drugs.
There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and twenty-eight supplementary protection certificates in ten countries.
Summary for Tris Pharma Inc
| International Patents: | 19 |
| US Patents: | 11 |
| Tradenames: | 28 |
| Ingredients: | 23 |
| NDAs: | 28 |
| Drug Master File Entries: | 6 |
| Patent Litigation for Tris Pharma Inc: | See patent lawsuits for Tris Pharma Inc |
Drugs and US Patents for Tris Pharma Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | METHYLPHENIDATE HYDROCHLORIDE | methylphenidate hydrochloride | SOLUTION;ORAL | 091601-001 | Jul 23, 2010 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tris Pharma Inc | IBUPROFEN | ibuprofen | SUSPENSION/DROPS;ORAL | 079058-001 | Aug 31, 2009 | OTC | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | 11,590,081 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Tris Pharma Inc | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 202214-005 | Mar 15, 2016 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tris Pharma Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009530298 | ⤷ Try a Trial |
| Canada | 2645855 | ⤷ Try a Trial |
| Spain | 2378573 | ⤷ Try a Trial |
| South Korea | 101495146 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tris Pharma Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0463756 | 5/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1441735 | SPC/GB08/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
